bio sensors presentation

8/2/2019 Bio Sensors Presentation

1/19


2/19

Who We Are

Biosensors develops, manufactures and markets

innovative medical devices for interventionalcardiology and critical care procedures.

Performance Risk Assessment Conclusion


3/19

Our Milestones


1990 Company Founded

2005 Listed on SGX Mainboard

2007 Acquired 50% interest in JWMS

2008 Received CE Mark for BioMatrixLaunched in Europe and Asia

2010 Hony Capital acquired majority stake in Biosesor

2011 Raised S$200 million (Alantis & Ever Union)

Fully acquired JWMS


4/19

Our Presence


5/19

More about us Market Capitalisation: S$2.25 billion Major shareholders:

Shandong Weigao

Hony Capital Fidelity Atlantis EverUnion

Total shares issued: 1.717 billion sharesPerformance Risk Assessment Conclusion


6/19

Management Team


Yoh Chie Lu, founder and Chairman President of Asia-Pacific division for BOC

Jeffrey Jump & Jack Wang, Co-CEO Over 30 years experience

John E. Shulze, Chief Technical Officer Primary architect of BioMatrix

Ronald H. Ede, Chief Financial Officer


7/19

Growing DES Industry

Vascular Interventional DevicesMarket

DESOthers76%

Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 2016)Global Trends & Competitive Analysis Report Code: MD 1752

Introduction Risk Assessment Conclusion


8/19

Growing DES Industry

0

5

10

15

2011 2016

Revenue Generated for Global DESMarket (US$ Billion)

8.9

13.7


Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 2016)Global Trends & Competitive Analysis Report Code: MD 1752


9/19

Our Business Model


General andAdministrative

Expenses

Research and

Development(R&D)

Otheroperatingexpenses

Sales and Marketing

Expenses


10/19

Abluminal Coating

Biolimus A9

S-Stent Platform

Biodegradable Polymer


11/19

The First Biodegradable DES - BioMatrix Strong clinical trial results Access to Chinas emerging market JWMS Next generation of DES- BioFreedom Strategic acquisition for technology development CardioMind Inc. AXXESSTM (Devax, Inc.)

Competitive Edge



12/19

Financial Highlights


Revenue

Profit

EPS

ROE

34.79%

34.98%

32.60%

48.42%


13/19

Liquidity: High

45.19

20.18

9.08

48.11 48.14

37.53

48.11 48.14

37.53

0

10

20

30

40

50

60

2009 2010 2011

GEARING RATIO COMPARISON

BIOSENSORS BOSTON SCIENTIFIC MEDTRONIC

1.06

2.17

5.35

1.52 1.391.72

2.07 2.37 1.92

0.00

1.00

2.00

3.00

4.00

5.00

6.00

2009 2010 2011

CURRENT RATIO COMPARISON




14/19

ROE Comparison


-1.08%

2.16%

11.43%

-8.66% -9.07%

3.88%

15.70%

21.11%19.39%

-15.00%

-10.00%

-5.00%

0.00%

5.00%

10.00%

15.00%

20.00%

25.00%

2009 2010 2011

ROE COMPARISON



15/19

Profitability and Efficiency

0.5993

0.5101

0.32760.3252 0.3528 0.3580

0.61890.5631

0.5237

0.0000

0.1000

0.2000

0.30000.4000

0.5000

0.6000

0.7000

2009 2010 2011

ASSET TURNOVER RATIOCOMPARISON


-0.94%

27.59% 27.63%

-13.01% -13.13%

5.79%

14.18%

19.59% 19.43%

-20.00%

-15.00%

-10.00%

-5.00%

0.00%

5.00%

10.00%

15.00%

20.00%

25.00%

30.00%

2009 2010 2011

NET PROFIT MARGINCOMPARISON




16/19

Growth Strategy

Expanding in China JW Medical Service Growing market

Penetrating the United States Largest global DES market

Expanding Product Portfolio



17/19

Risk Assessment Preferred supplier agreements Declining prices of DES Competition from local manufacturers Regulatory Requirement

Introduction Performance Conclusion


18/19

We make dollars and stents Every 2 seconds someone has a heart attack Access to growing markets

3 Reasons to Invest

Introduction Performance


19/19

Q&A

bio sensors presentation

Documents